Style | Citing Format |
---|---|
MLA | Abedi Kiasari B, et al.. "Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy." International Immunopharmacology, vol. 113, no. , 2022, pp. -. |
APA | Abedi Kiasari B, Abbasi A, Ghasemi Darestani N, Adabi N, Moradian A, Yazdani Y, Sadat Hosseini G, Gholami N, Janati S (2022). Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy. International Immunopharmacology, 113(), -. |
Chicago | Abedi Kiasari B, Abbasi A, Ghasemi Darestani N, Adabi N, Moradian A, Yazdani Y, Sadat Hosseini G, Gholami N, Janati S. "Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy." International Immunopharmacology 113, no. (2022): -. |
Harvard | Abedi Kiasari B et al. (2022) 'Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy', International Immunopharmacology, 113(), pp. -. |
Vancouver | Abedi Kiasari B, Abbasi A, Ghasemi Darestani N, Adabi N, Moradian A, Yazdani Y, et al.. Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy. International Immunopharmacology. 2022;113():-. |
BibTex | @article{ author = {Abedi Kiasari B and Abbasi A and Ghasemi Darestani N and Adabi N and Moradian A and Yazdani Y and Sadat Hosseini G and Gholami N and Janati S}, title = {Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy}, journal = {International Immunopharmacology}, volume = {113}, number = {}, pages = {-}, year = {2022} } |
RIS | TY - JOUR AU - Abedi Kiasari B AU - Abbasi A AU - Ghasemi Darestani N AU - Adabi N AU - Moradian A AU - Yazdani Y AU - Sadat Hosseini G AU - Gholami N AU - Janati S TI - Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy JO - International Immunopharmacology VL - 113 IS - SP - EP - PY - 2022 ER - |